Magistrado Pamela A, Corey Victoria C, Lukens Amanda K, LaMonte Greg, Sasaki Erika, Meister Stephan, Wree Melanie, Winzeler Elizabeth, Wirth Dyann F
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health , Boston, Massachusetts 02115, United States.
School of Medicine, University of California-San Diego , La Jolla, California 92093, United States.
ACS Infect Dis. 2016 Nov 11;2(11):816-826. doi: 10.1021/acsinfecdis.6b00025. Epub 2016 Apr 7.
MMV007564 is a novel antimalarial benzimidazolyl piperidine chemotype identified in cellular screens. To identify the genetic determinant of MMV007564 resistance, parasites were cultured in the presence of the compound to generate resistant lines. Whole genome sequencing revealed distinct mutations in the gene named Plasmodium falciparum cyclic amine resistance locus (pfcarl), encoding a conserved protein of unknown function. Mutations in pfcarl are strongly associated with resistance to a structurally unrelated class of compounds, the imidazolopiperazines, including KAF156, currently in clinical trials. Our data demonstrate that pfcarl mutations confer resistance to two distinct compound classes, benzimidazolyl piperidines and imidazolopiperazines. However, MMV007564 and the imidazolopiperazines, KAF156 and GNF179, have different timings of action in the asexual blood stage and different potencies against the liver and sexual blood stages. These data suggest that pfcarl is a multidrug-resistance gene rather than a common target for benzimidazolyl piperidines and imidazolopiperazines.
MMV007564是在细胞筛选中鉴定出的一种新型抗疟苯并咪唑基哌啶化学类型。为了确定MMV007564抗性的遗传决定因素,将疟原虫在该化合物存在下培养以产生抗性品系。全基因组测序揭示了名为恶性疟原虫环胺抗性位点(pfcarl)的基因中的独特突变,该基因编码一种功能未知的保守蛋白。pfcarl中的突变与对一类结构不相关的化合物(咪唑并哌嗪)的抗性密切相关,包括目前正在临床试验中的KAF156。我们的数据表明,pfcarl突变赋予了对两种不同化合物类别的抗性,即苯并咪唑基哌啶和咪唑并哌嗪。然而,MMV007564与咪唑并哌嗪KAF156和GNF179在无性血液阶段具有不同的作用时间,并且对肝脏和有性血液阶段具有不同的效力。这些数据表明,pfcarl是一个多药抗性基因,而不是苯并咪唑基哌啶和咪唑并哌嗪的共同靶点。